DRAIC and prostate carcinoma: In a more recent paper, the authors have shown that a specific metabolite named 5-alpha-Abi of Abiraterone, which is a steroidgenesis enzyme inhibitor for the treatment of metastatic castration resistant prostate cancer, could induce DRAIC expression, indicating DRAIC’s involvement in anti-androgen therapy resistance for prostate cancer [15].